Factors | PVP group | Combination therapy group | P value |
---|---|---|---|
age | 61.35 ± 3.04 | 60.87 ± 3.68 | 0.574 |
Gender | |||
 Male | 17 | 19 | 0.614 |
 Female | 14 | 12 | |
Primary tumor | |||
 Prostate cancer | 14 | 15 | 0.809 |
 Lung cancer | 8 | 7 | |
 Breast cancer | 7 | 8 | |
 Bladder cancer | 1 | 0 | |
 Duodenal papillary adenocarcinoma | 1 | 1 | |
Metastatic site | |||
 Lumbar spine | 10 | 11 | 0.878 |
 Sacral spine | 9 | 12 | |
 Lumbar and sacral spine | 12 | 8 | |
Spinal segment | |||
 1 segment | 8 | 10 | 0.211 |
 2 segments | 10 | 12 | |
  ≥ 3 segments | 13 | 9 | |
 VAS score | 8.71 ± 0.34 | 8.68 ± 0.33 | 0.734 |
 KPS score | 65.29 ± 4.59 | 67.71 ± 5.89 | 0.076 |